SNAC uses structural and advanced image analysis to further the understanding of neurological disorders, and develop tailored imaging biomarkers for clinical trials of emerging therapeutics.
Our quantitative biomarker research has been translated to Phase 2 clinical trials of emerging pro-remyelinating therapies; and composite MRI-electrophysiology studies have yielded new insights into sub-clinical, disease-related injury to brain structure-function networks.
